Cadila Healthcare rises after DCGI nods Phase 3 trial of Pegylated Interferon Alpha-2b

Cadila Healthcare rose 0.72% to Rs 466.15 after the company received approval from DCGI to commence Phase III clinical trials with Pegylated Interferon alpha-2b in India.

The drug major on Friday (4 December 2020) announced that it received an approval from the Drugs Controller General of India (DCGI) to start the Phase 3 clinical trial in CoVID-19 patients with its biological therapy, Pegylated Interferon alpha-2b, 'PegiHep'. The trials which will commence in December will be conducted on 250 patients across 20-25 centres in India.

In the Phase II clinical trials study established the early safety, efficacy and tolerability of PegiHep and has indicated that Pegylated Interferon alpha-2b having statistical clinical beneficial impact on the patient suffering from moderate COVID 19 disease by reducing their viral load helping in better disease management such as reduced duration of oxygen support. Moreover, a single dose therapy will improve compliance and also make it highly affordable for patients. Pegylated Interferon alpha-2b, 'PegiHep' is an approved drug and is being re-purposed for the treatment of COVID-19.

Zydus Cadila is also conducting a similar Phase 2 trial in Mexico. The company is also working with the USFDA to open an Investigational New Drug (IND) application for Pegylated Interferon alpha-2b in order to initiate appropriate clinical trials in US.

Cadila Healthcare is a global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.

The company's consolidated net profit soared 411% to Rs 423.60 crore on 16% jump in net sales to Rs 3,762.30 crore in Q2 September 2020 over Q2 September 2019.

Powered by Capital Market - Live News